Latest news with #NERO
Business Insider
28-07-2025
- Business
- Business Insider
Bitget Lists NERO Chain (NERO) for Spot Trading with 65M in Token Rewards
Seychelles, Victoria, July 28th, 2025, Chainwire Bitget, the leading cryptocurrency exchange and Web3 company, has announced the listing of NERO Chain (NERO) in the Innovation and Public Chain Zone, adding it for spot trading. Trading for the NERO/USDT pair will begin on 28 July 2025, 7:00 (UTC), with withdrawals available from 29 July 2025, 8:00 (UTC). Alongside the listing, Bitget will launch a CandyBomb campaign with 65,000,000 NERO available in rewards. Of this, 7,500,000 NERO will be allocated to the NERO, ETH and SUI trading pool, 15,000,000 NERO in the NERO trading pool, while 42,500,000 NERO will be up for grabs in the ETH and SUI trading pool. The campaign will run from 28 July 2025, 7:00 till 4 August 2025, 7:00 (UTC). NERO Chain is a modular blockchain designed to prioritize value creation for applications rather than relying solely on infrastructure-level storage. It redefines traditional blockchain economics by enabling dApps to capture and share transaction value, ensuring that developers and users benefit directly from an application's success, rather than value accruing solely to the base layer. Fully EVM-compatible and built on a high-performance settlement layer, NERO offers powerful scalability and flexibility. Features like native account abstraction, gas sponsorship through paymasters, and cutting-edge innovations such as Blockspace 2.0 provide developers with a seamless and efficient building experience. Bitget continues to expand its offerings, positioning itself as a leading platform for cryptocurrency trading. The exchange has established a reputation for innovative solutions that empower users to explore crypto within a secure CeDeFi ecosystem. With an extensive selection of over 800 cryptocurrency pairs and a commitment to broaden its offerings to more than 900 trading pairs, Bitget connects users to various ecosystems, including Bitcoin, Ethereum, Solana, Base, and TON. The addition of NERO into Bitget's portfolio marks a significant step toward expanding its ecosystem by advancing privacy-focused infrastructure and enabling seamless migration of Web2 applications into the Web3 space through scalable, developer-friendly solutions. For more details on NERO, visit here. About Bitget Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Formerly known as BitKeep, Bitget Wallet is a leading non-custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi-chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built into a single platform. Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets, as well as a global partner of Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team), to inspire the global community to embrace the future of cryptocurrency. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP, one of the world's most thrilling championships. For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet For media inquiries, please contact: media@ Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.
Yahoo
30-04-2025
- Health
- Yahoo
GSK's Zejula reduces risk of progression and death in mesothelioma study
GSK's Zejula (niraparib) has reduced the risk of death or progression by 27% in patients with mesothelioma in an investigator-led Phase II trial. The NERO study (NCT05455424) investigated the efficacy of Zejula in 88 mesothelioma patients who relapsed after previously receiving platinum-based systemic therapy. The study is sponsored by the University Hospital Southampton NHS Foundation Trust and funded by Asthma + Lung UK, with support from Mesothelioma UK and the Mavis Nye Foundation. Mesothelioma is a highly aggressive cancer that forms in the protective lining surrounding certain internal organs, most commonly the lungs, and is usually linked to asbestos exposure. Treatments are limited, and the standard of care (SOC) includes surgery, chemotherapy, radiation therapy, and immunotherapy. Those treated with Zejula benefited from an average of 1.5 months progression-free survival (PFS) compared to SOC – marking a 27% reduction in the risk of the cancer progressing or death. Professor Gareth Griffiths, director of the Southampton Clinical Trials Unit and co-lead of the trial, said: 'Although this increase may seem small, for this group of patients who have very few treatment options and a generally poor prognosis, this is a significant step forward. "We have shown for the first time that this kind of drug can improve progression-free survival for mesothelioma patients compared with their usual treatment in the NHS. This gives enormous hope to those patients and their families and means we can now carry out further research to find out more about how these treatments could be tailored and enhanced to stimulate an even better response in more people.' The data was presented at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, US, on 29 April. The University Hospital Southampton NHS Foundation Trust is now keen to initiate a new study, SELECTmeso, which will be a Phase II platform trial in patients with confirmed histological diagnosis of mesothelioma with evidence of MTAP loss on immunohistochemistry, and evidence of disease progression following prior standard systemic therapy on CT scan. Griffiths added: 'This trial will see patients tested for certain biomarkers, or genetic signals, in their tumours and then given the drug that is most likely to work for them. We really hope this step into more personalised medicine could further help these patients who desperately need better treatment options.' Zejula is an oral poly-ADP ribose polymerase (PARP) inhibitor that was approved on 27 March 2017 by the US Food and Drug Administration (FDA) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Other PARP inhibitors being investigated in patients with mesothelioma include AstraZeneca's Lynparza (olaparib), which is currently in a Phase II trial (NCT04515836); and Pfizer's Talzenna (talazoparib), which is also in a Phase II study (NCT04462809). AstraZeneca is also studying volrustomig, a bispecific antibody immunotherapy that targets and blocks PD-1 and CTLA-4. The drug is currently being evaluated in a Phase III trial for malignant pleural mesothelioma (NCT06097728). In September 2024, the FDA approved MSD's Keytruda in combination with chemotherapy as a treatment for unresectable advanced or metastatic malignant pleural mesothelioma, based on data from the KEYNOTE-483 (NCT02784171) study. "GSK's Zejula reduces risk of progression and death in mesothelioma study" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
BBC News
30-04-2025
- Health
- BBC News
Trial gives new hope for patients with asbestos-linked cancer
For the first time researchers in Southampton have used a drug to slow the growth of an asbestos-linked is an aggressive cancer that forms in the lining of the lungs or abdomen and is linked to breathing in or ingesting dangerous asbestos have said the breakthrough gives new hope to patients who have exhausted traditional treatments, and could give them more time with their loved Gareth Griffiths, director of the Southampton Clinical Trials Unit and co-lead of the trial, called it "a significant step forward". James Fox, from Dorset, was diagnosed with mesothelioma in 2018 and given less than a year to tried other treatment options, he was offered the chance to join the new drug trial, and said the results had been an architect, in the 70's and 80's he was exposed to asbestos, which has now been linked to his aggressive cancer, with only 5% of those diagnosed surviving for five years or Fox said: "I've had seven really good years and been able to enjoy life almost to the full so that's wonderful. "So far it's been almost a miracle in my case." The trial was run by researchers at the University of Leicester and the Cancer Research UK Southampton Clinical Trials Unit, with funding provided by the charity Asthma + Lung the NERO trial, it looked at a class of drug known as PARP inhibitors, which work by blocking the repair of damaged DNA in cancer cells, thereby causing the cancer cells to inhibitors have already been shown to improve the survival of patients with some types of breast and ovarian cancers. A previous study had also shown that mesothelioma does respond to this type of drug, but more evidence was needed as to whether it could improve outcomes for 11 hospitals across the UK, 88 patients whose mesothelioma treatment had stopped working took part in the trial. 'Enormous hope' Those given a PARP inhibitor called niraparib were found to have a 27% reduction in the risk of the cancer progressing or death. This delayed the worsening of mesothelioma by an average of 1.5 months compared to those receiving the standard of care treatments, with a number of patients seeing a much longer period of time where their cancer was being Griffiths said: "We have shown for the first time that this kind of drug can improve progression-free survival for mesothelioma patients compared with their usual treatment in the NHS. "This gives enormous hope to those patients and their families and means we can now carry out further research to find out more about how these treatments could be tailored and enhanced to stimulate an even better response in more people." For Mr Fox, who has five grand children, the treatment has surpassed all his expectations."It's dramatic, the improvement, I don't think this could have possibly happened without this particular drug, without being offered it. "It must be the drug that's been keeping me fit and alive, so I'm very grateful for that." You can follow BBC Hampshire & Isle of Wight on Facebook, X (Twitter), or Instagram.
